Literature DB >> 20731268

Limbic encephalitis presenting with seizures, anterograde amnesia, and psychosis in a patient seven weeks status post immature ovarian teratoma removal.

Brian Kleyensteuber1, Victor Ruterbusch, Jason Bennett, David Llewellyn, George Loeffler.   

Abstract

A paraneoplastic syndrome associated with anti-N-methyl-D-asparate (NMDA) receptors can initially present as a neurologic or psychiatric disturbance. Removal of the tumor is usually curative, and the syndrome is associated with the presence, rather than the history, of tumor. We present a case in which a 25-year-old, Hispanic woman presented with seizures, memory loss, and unusual behavioral changes. The woman had a teratoma removed 2 months earlier. Because of the time course, a paraneoplastic syndrome was initially considered unlikely. Brain imaging, electroencephalography (EEG) and neurologic work-up were negative. The patient was treated for a suspected somatoform disorder and psychosis. Based on the clinical picture, the working diagnosis was changed to delirium due to paraneoplastic limbic encephalitis. A course of intravenous immunoglobins (IVIg), and high dose steroids was administered. The patient's symptoms improved, and she was discharged home. After discharge, studies came back positive for antibodies against NR1/NR2 of the NMDA receptor.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20731268     DOI: 10.7205/milmed-d-09-00250

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  2 in total

1.  Status epilepticus and anti-NMDA receptor encephalitis after resection of an ovarian teratoma.

Authors:  Amritpal S Jandu; Peter M Odor; Steven D Vidgeon
Journal:  J Intensive Care Soc       Date:  2016-03-18

2.  Ovarian teratoma-associated anti-NMDAR encephalitis: a systematic review of reported cases.

Authors:  Pedro Acién; Maribel Acién; Eva Ruiz-Maciá; Carlos Martín-Estefanía
Journal:  Orphanet J Rare Dis       Date:  2014-10-14       Impact factor: 4.123

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.